Compare POWW & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POWW | SLN |
|---|---|---|
| Founded | 1990 | 1994 |
| Country | United States | United Kingdom |
| Employees | 81 | 116 |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 242.8M | 236.2M |
| IPO Year | N/A | N/A |
| Metric | POWW | SLN |
|---|---|---|
| Price | $1.96 | $7.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | $2.40 | ★ $42.60 |
| AVG Volume (30 Days) | ★ 496.3K | 367.8K |
| Earning Date | 02-09-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.56 | N/A |
| Revenue Next Year | $0.50 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.08 | $4.19 |
| 52 Week High | $2.23 | $8.40 |
| Indicator | POWW | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 43.03 | 53.04 |
| Support Level | $1.89 | $5.91 |
| Resistance Level | $1.98 | $7.21 |
| Average True Range (ATR) | 0.07 | 0.45 |
| MACD | -0.01 | -0.11 |
| Stochastic Oscillator | 23.08 | 27.33 |
Outdoor Holding Co Formerly AMMO Inc is the owner of GunBroker.com, the online marketplace serving the firearms and shooting sports industries, and a vertically integrated producer of high-performance ammunition and components. It engages in the design, manufacture, and market of ammunition products in the Shooting sports industry in the United States. The firm's product segment comprises Ammunition and Marketplace. The Ammunition segment engages in the design, production, and marketing of ammunition and ammunition component products and the marketplace segment consists of the GunBroker.com marketplace. The company generates the majority of its revenue from the Ammunition segment.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.